Adolor Abandons Entereg Chronic OBD Indication, Faces Other Setbacks
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adolor is abandoning development of Entereg (alvimopan) for chronic opioid bowel dysfunction just three months after its post-operative ileus partner, GlaxoSmithKline, returned rights for chronic indications
You may also be interested in...
Entereg Documents Offer Detailed Insight Into REMS Review Process
GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.
Adolor Seeks New Entereg Partner; Asks FDA To Weigh In On Chronic Use
GSK returns rights to alvimopan in outpatient settings; partnership continues for approved hospital use.
Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.